This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Angiostatin

Alchemgen Therapeutics, Inc.

Drug Names(s): Recombinant Angiostatin Protein

Description: In many ways, Angiostatin is similar to Endostatin. Both are formulations of naturally occuring protein fragments. Angiostatin is a cleavage product of proplasminogen.

Deal Structure: In February 2004, EntreMed transferred all rights and developmental responsibilities for endostatin and angiostatin to the Childrens Medical Center Corporation (CMCC) and Alchemgen Therapeutics. Under the agreement, CMCC and Alchemgen are continuing the development of endostatin and angiostatin and bear all expenses associated with the programs. In exchange, EntreMed receives upfront and future cash and royalty payments.

EntreMed and CASI
In June 2014, EntreMed announced that at its annual meeting of stockholders, stockholders voted in favor of changing the companys corporate name to CASI Pharmaceuticals, Inc.

Partners: CASI Pharmaceuticals, Inc.


Angiostatin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug